Global Microbiome Therapeutics Market: Focus on Target Therapies, Region (10 Countries), and Competitive Landscape - Analysis and Forecast, 2019-2030
Hard copy option is available on any of the options above at an additional charge of $500. Please email us at [email protected] with your request.
Market Report Coverage - Microbiome Therapeutics
Market Segmentation
4D PHARMA PLC, AOBIOME, SANOFI S.A, FERRING PHARMACEUTICALS, FINCH THERAPEUTICS, IMMURON LIMITED, OXTHERA AB, AMONG OTHERS
Key Questions Answered in this Report:
Microbiome is defined as the collective genomes of the microbes (composed of fungi, bacteria, bacteriophage, viruses, and protozoa) that live inside and on the body.
Clinical studies on various microbiomes have been significantly growing during the past decade, owing to the considerable reduction in the cost of DNA sequencing, enabling the microbes in their complex mixture to be defined by their genome. Research findings have generated information about the role of the microorganism population in determining human health. The microbiome is found to play a role in inflammatory bowel disease (IBD), allergies, and immune-oncology, among others. Microbiome has become an attractive target for potential therapeutics owing to its extensive role in gastrointestinal and non-gastrointestinal diseases. However, there are challenges associated with microbiome research. Determining the cause-effect relationships and designing microbiome-based therapies that can attain effective results on the human health and microbial community are among such challenges.
Several players, such as Sanofi S.A and Taisho Pharmaceuticals, are currently offering these microbiome therapeutics in the market. The entry of new players in the market, coupled with increased innovation pertaining to therapeutic output maximization with minimal side effects, has transformed the market currently.
The existing market of microbiome therapeutics is favored by multiple factors, which include the rising geriatric populations coupled with the increased financing and the increasing adoption of inorganic growth strategies by key players in the market.
Within the research report, the market is segmented on the basis of target therapy area (gastrointestinal and infectious diseases, and other diseases) and region (North America, Europe, Asia-Pacific, and Rest-of-the-World). This segmentation highlights value propositions and business models useful for industry leaders and stakeholders. The research also comprises country-level analysis, go-to-market strategies of leading players, future opportunities, among others, to detail the scope and provide a 360-coverage of the domain.
Competitive Landscape
Major players, including 4D Pharma, Enterome, and Finch Therapeutics, led the number of synergistic developments (partnerships and alliances) witnessed by the market. On the basis of region, Asia-Pacific is expected to retain a leading position throughout the forecast period 2020-2030, followed by Europe. This is a result of the presence of leading industry players in this region, coupled up with soaring clinical activities pertaining to the development of microbiome therapeutics.
Market Report Coverage - Microbiome Therapeutics
Market Segmentation
- By Disease Type: Gastrointestinal and Infectious Diseases and Other Diseases
- By Region: North America, Europe, Asia-Pacific, and Rest-of-the-World
- North America – U.S., Canada
- Europe – Germany, U.K., France, Sweden, and Rest-of-Europe
- Asia-Pacific – China, Australia, Japan, India, and Rest-of-Asia-Pacific
- Rest-of-the-World
- Increasing adoption of inorganic growth strategies in the market
- Significant external funding for executing research and therapeutic innovation
- Payer uncertainty and outcome-based pricing
- Insufficient Application-Based Research Hindering Market Pull
- Entry of major players for the development of microbiome therapeutics
- Growing eminence of microbiome therapeutics in cancer treatment
4D PHARMA PLC, AOBIOME, SANOFI S.A, FERRING PHARMACEUTICALS, FINCH THERAPEUTICS, IMMURON LIMITED, OXTHERA AB, AMONG OTHERS
Key Questions Answered in this Report:
- What is microbiome therapeutics? How have different target therapy area settings for microbiome therapeutics evolved over the centuries?
- What are the major market drivers, challenges, and opportunities in the global microbiome therapeutics market?
- What was the global microbiome therapeutics market size in terms of revenue in 2019? How is the market expected to evolve in the upcoming years? What is the expected market size in 2030?
- How is each segment of the global microbiome therapeutics market expected to grow during the forecast period 2020-2030, and what is the estimated revenue expected to be generated by each of the segments by the end of 2030?
- What are the developmental strategies implemented by the key players to sustain in the competitive market?
- What is the growth potential of the global microbiome therapeutics in several countries globally?
- Which target therapy area segment among the two gastrointestinal and infectious diseases and other therapy areas are offered or being developed by key players such as Taisho Pharmaceuticals, Immuron Limited, Sanofi S.A., and Rebiotix?
- Which target therapy area segment led the market in 2019 and is expected to dominate the market in 2030, and why?
- Which region dominated the global microbiome therapeutics market in 2019, and what are the anticipated trends from each of the regions in the forecast period 2020-2030?
Microbiome is defined as the collective genomes of the microbes (composed of fungi, bacteria, bacteriophage, viruses, and protozoa) that live inside and on the body.
Clinical studies on various microbiomes have been significantly growing during the past decade, owing to the considerable reduction in the cost of DNA sequencing, enabling the microbes in their complex mixture to be defined by their genome. Research findings have generated information about the role of the microorganism population in determining human health. The microbiome is found to play a role in inflammatory bowel disease (IBD), allergies, and immune-oncology, among others. Microbiome has become an attractive target for potential therapeutics owing to its extensive role in gastrointestinal and non-gastrointestinal diseases. However, there are challenges associated with microbiome research. Determining the cause-effect relationships and designing microbiome-based therapies that can attain effective results on the human health and microbial community are among such challenges.
Several players, such as Sanofi S.A and Taisho Pharmaceuticals, are currently offering these microbiome therapeutics in the market. The entry of new players in the market, coupled with increased innovation pertaining to therapeutic output maximization with minimal side effects, has transformed the market currently.
The existing market of microbiome therapeutics is favored by multiple factors, which include the rising geriatric populations coupled with the increased financing and the increasing adoption of inorganic growth strategies by key players in the market.
Within the research report, the market is segmented on the basis of target therapy area (gastrointestinal and infectious diseases, and other diseases) and region (North America, Europe, Asia-Pacific, and Rest-of-the-World). This segmentation highlights value propositions and business models useful for industry leaders and stakeholders. The research also comprises country-level analysis, go-to-market strategies of leading players, future opportunities, among others, to detail the scope and provide a 360-coverage of the domain.
Competitive Landscape
Major players, including 4D Pharma, Enterome, and Finch Therapeutics, led the number of synergistic developments (partnerships and alliances) witnessed by the market. On the basis of region, Asia-Pacific is expected to retain a leading position throughout the forecast period 2020-2030, followed by Europe. This is a result of the presence of leading industry players in this region, coupled up with soaring clinical activities pertaining to the development of microbiome therapeutics.
Executive Summary
1 PRODUCT DEFINITION
1.1 Inclusion and Exclusion
2 MARKET SCOPE
2.1 Scope of Work
2.2 Key Questions Answered in the Report
3 RESEARCH METHODOLOGY
3.1 Global Microbiome Therapeutics Market: Research Methodology
3.2 Data Sources
3.3 Secondary Data Sources
3.4 Market Estimation Model
3.5 Criteria for Company Profiling
4 MARKET OVERVIEW
4.1 Market Size and Future Growth Potential
4.2 Historical Trends
5 INDUSTRY INSIGHTS
5.1 Regulatory Landscape
5.1.1 Regulatory Requirements for Live Biotherapeutic Products (LBPs)
5.2 Patent Landscape
5.2.1 Patent Filing Analysis
5.2.2 Key Players Patent Portfolio
5.2.3 Key Players Patent Expiration Analysis
5.3 Financing Landscape
5.3.1 Financing Stratification (as Per Raised Financing Value)
5.3.2 Year on Year Financing Analysis (FY2017-3Q2020)
5.3.3 Investment Heat Map
5.4 Pipeline Landscape
5.4.1 Competitive Landscaping
5.4.2 Pipeline Analysis
5.4.2.1 By Developmental Phase
5.4.2.2 By Route of Administration
5.4.2.3 By Type of Microbiome Strategy
5.4.2.4 By Target Therapy Area
5.5 Partnership Landscape
5.6 Government Initiatives
6 MARKET DYNAMICS
6.1 Market Drivers
6.1.1 Significant External Funding for Executing Research and Therapeutic Innovation
6.1.2 Increasing Adoption of Inorganic Growth Strategies in the Market
6.2 Market Restraints
6.2.1 Payer Uncertainty and Outcome-Based Pricing
6.2.2 Insufficient Application-Based Research Hindering Market Pull
6.2.3 FMT Manufacturing Issues
6.3 Market Opportunities
6.3.1 Entry of Major Players for the Development of Microbiome Therapeutics
6.3.2 Growing Eminence of Microbiome Therapeutics in Cancer Treatment
7 COMPETITIVE INSIGHTS
7.1 Key Strategies and Developments
7.2 Synergistic Activities
7.3 Regulatory Accreditations
7.4 Mergers and Acquisitions
7.5 Market Share Analysis
7.6 Growth Share Analysis (Opportunity Mapping)
7.6.1 By Geography
7.6.2 By Company
8 GLOBAL MICROBIOME THERAPEUTICS MARKET (BY TARGET THERAPY AREA)
8.1 Overview
8.2 Gastrointestinal and Infectious Diseases
8.3 Other Diseases
9 GLOBAL MICROBIOME THERAPEUTICS MARKET (BY REGION)
9.1 Overview
9.2 North America
9.2.1 Overview
9.2.2 U.S.
9.2.3 Canada
9.3 Europe
9.3.1 Overview
9.3.2 France
9.3.3 Sweden
9.3.4 Germany
9.3.5 U.K.
9.3.6 Rest-of-Europe
9.4 Asia-Pacific (APAC)
9.4.1 Overview
9.4.2 Japan
9.4.3 Australia
9.4.4 China
9.4.5 India
9.4.6 Rest-of-Asia-Pacific
9.5 Rest-of-the-World
9.5.1 Overview
10 COMPANY PROFILES
10.1.1 Overview
10.2 4D Pharma plc
10.2.1 Company Overview
10.2.2 Role of 4D Pharma plc in Global Microbiome Therapeutics Market
10.2.3 Financials
10.2.4 SWOT Analysis
10.3 AOBiome
10.3.1 Company Overview
10.3.2 Role of AOBiome in the Global Microbiome Therapeutics Market
10.3.3 SWOT Analysis
10.4 Finch Therapeutics
10.4.1 Company Overview
10.4.2 Role of Finch Therapeutics in Global Microbiome Therapeutics Market
10.4.3 SWOT Analysis
10.5 Ferring Pharmaceuticals
10.5.1 Company Overview
10.5.2 Rebiotix Inc. (A Subsidiary of Ferring Pharmaceuticals)
10.5.3 Company Overview
10.5.4 Role of Rebiotix Inc. in Global Microbiome Therapeutics Market
10.5.5 SWOT Analysis
10.6 Immuron Limited
10.6.1 Company Overview
10.6.2 Role of Immuron in Global Microbiome Therapeutics Market
10.6.3 Financials
10.6.4 SWOT Analysis
10.7 MaaT Pharma
10.7.1 Company Overview
10.7.2 Role of MaaT Pharma in Global Microbiome Therapeutics Market
10.7.3 SWOT Analysis
10.8 Naked Biome
10.8.1 Company Overview
10.8.2 Role of Naked Biome in Global Microbiome Therapeutics Market
10.8.3 SWOT Analysis
10.9 OxThera AB
10.9.1 Company Overview
10.9.2 Role of OxThera AB in Global Microbiome Therapeutics Market
10.9.3 SWOT Analysis
10.1 Quorum Innovations
10.10.1 Company Overview
10.10.2 Role of Quorum Innovations, LLC in Global Microbiome Therapeutics Market
10.10.3 SWOT Analysis
10.11 Sanofi S.A.
10.11.1 Company Overview
10.11.2 Role of Sanofi S.A. in Global Microbiome Therapeutics Market
10.11.3 Financials
10.11.4 Key Insights About the Financial Health of the Company
10.11.5 SWOT Analysis
10.12 Seres Therapeutics, Inc.
10.12.1 Company Overview
10.12.2 Role of Seres Therapeutics, Inc. in Global Microbiome Therapeutics Market
10.12.3 Financials
10.12.4 Key Insights About Financial Health of the Company
10.12.5 SWOT Analysis
10.13 Synthetic Biologics
10.13.1 Company Overview
10.13.2 Role of Synthetic Biologics, Inc. in Global Microbiome Therapeutics Market
10.13.3 Financials
10.13.4 SWOT Analysis
10.14 Taisho Pharmaceutical
10.14.1 Company Overview
10.14.2 Biofermin Pharmaceutical Co. Ltd. (A Subsidiary of Taisho Pharmaceutical)
10.14.3 Company Overview
10.14.4 Role of Taisho Pharmaceutical in Global Microbiome Therapeutics Market
10.14.5 Financial
10.14.6 Key Insights about the Financial Health of the Company
10.14.7 SWOT Analysis
10.15 Vedanta Biosciences, Inc.
10.15.1 Company Overview
10.15.2 Role of Vedanta Biosciences, Inc. in Global Microbiome Therapeutics Market
10.15.3 SWOT Analysis
10.16 Pendulum Therapeutics
10.16.1 Company Overview
10.16.2 Role of Pendulum Therapeutics in Global Microbiome Therapeutics Market
10.16.3 SWOT Analysis
1 PRODUCT DEFINITION
1.1 Inclusion and Exclusion
2 MARKET SCOPE
2.1 Scope of Work
2.2 Key Questions Answered in the Report
3 RESEARCH METHODOLOGY
3.1 Global Microbiome Therapeutics Market: Research Methodology
3.2 Data Sources
3.3 Secondary Data Sources
3.4 Market Estimation Model
3.5 Criteria for Company Profiling
4 MARKET OVERVIEW
4.1 Market Size and Future Growth Potential
4.2 Historical Trends
5 INDUSTRY INSIGHTS
5.1 Regulatory Landscape
5.1.1 Regulatory Requirements for Live Biotherapeutic Products (LBPs)
5.2 Patent Landscape
5.2.1 Patent Filing Analysis
5.2.2 Key Players Patent Portfolio
5.2.3 Key Players Patent Expiration Analysis
5.3 Financing Landscape
5.3.1 Financing Stratification (as Per Raised Financing Value)
5.3.2 Year on Year Financing Analysis (FY2017-3Q2020)
5.3.3 Investment Heat Map
5.4 Pipeline Landscape
5.4.1 Competitive Landscaping
5.4.2 Pipeline Analysis
5.4.2.1 By Developmental Phase
5.4.2.2 By Route of Administration
5.4.2.3 By Type of Microbiome Strategy
5.4.2.4 By Target Therapy Area
5.5 Partnership Landscape
5.6 Government Initiatives
6 MARKET DYNAMICS
6.1 Market Drivers
6.1.1 Significant External Funding for Executing Research and Therapeutic Innovation
6.1.2 Increasing Adoption of Inorganic Growth Strategies in the Market
6.2 Market Restraints
6.2.1 Payer Uncertainty and Outcome-Based Pricing
6.2.2 Insufficient Application-Based Research Hindering Market Pull
6.2.3 FMT Manufacturing Issues
6.3 Market Opportunities
6.3.1 Entry of Major Players for the Development of Microbiome Therapeutics
6.3.2 Growing Eminence of Microbiome Therapeutics in Cancer Treatment
7 COMPETITIVE INSIGHTS
7.1 Key Strategies and Developments
7.2 Synergistic Activities
7.3 Regulatory Accreditations
7.4 Mergers and Acquisitions
7.5 Market Share Analysis
7.6 Growth Share Analysis (Opportunity Mapping)
7.6.1 By Geography
7.6.2 By Company
8 GLOBAL MICROBIOME THERAPEUTICS MARKET (BY TARGET THERAPY AREA)
8.1 Overview
8.2 Gastrointestinal and Infectious Diseases
8.3 Other Diseases
9 GLOBAL MICROBIOME THERAPEUTICS MARKET (BY REGION)
9.1 Overview
9.2 North America
9.2.1 Overview
9.2.2 U.S.
9.2.3 Canada
9.3 Europe
9.3.1 Overview
9.3.2 France
9.3.3 Sweden
9.3.4 Germany
9.3.5 U.K.
9.3.6 Rest-of-Europe
9.4 Asia-Pacific (APAC)
9.4.1 Overview
9.4.2 Japan
9.4.3 Australia
9.4.4 China
9.4.5 India
9.4.6 Rest-of-Asia-Pacific
9.5 Rest-of-the-World
9.5.1 Overview
10 COMPANY PROFILES
10.1.1 Overview
10.2 4D Pharma plc
10.2.1 Company Overview
10.2.2 Role of 4D Pharma plc in Global Microbiome Therapeutics Market
10.2.3 Financials
10.2.4 SWOT Analysis
10.3 AOBiome
10.3.1 Company Overview
10.3.2 Role of AOBiome in the Global Microbiome Therapeutics Market
10.3.3 SWOT Analysis
10.4 Finch Therapeutics
10.4.1 Company Overview
10.4.2 Role of Finch Therapeutics in Global Microbiome Therapeutics Market
10.4.3 SWOT Analysis
10.5 Ferring Pharmaceuticals
10.5.1 Company Overview
10.5.2 Rebiotix Inc. (A Subsidiary of Ferring Pharmaceuticals)
10.5.3 Company Overview
10.5.4 Role of Rebiotix Inc. in Global Microbiome Therapeutics Market
10.5.5 SWOT Analysis
10.6 Immuron Limited
10.6.1 Company Overview
10.6.2 Role of Immuron in Global Microbiome Therapeutics Market
10.6.3 Financials
10.6.4 SWOT Analysis
10.7 MaaT Pharma
10.7.1 Company Overview
10.7.2 Role of MaaT Pharma in Global Microbiome Therapeutics Market
10.7.3 SWOT Analysis
10.8 Naked Biome
10.8.1 Company Overview
10.8.2 Role of Naked Biome in Global Microbiome Therapeutics Market
10.8.3 SWOT Analysis
10.9 OxThera AB
10.9.1 Company Overview
10.9.2 Role of OxThera AB in Global Microbiome Therapeutics Market
10.9.3 SWOT Analysis
10.1 Quorum Innovations
10.10.1 Company Overview
10.10.2 Role of Quorum Innovations, LLC in Global Microbiome Therapeutics Market
10.10.3 SWOT Analysis
10.11 Sanofi S.A.
10.11.1 Company Overview
10.11.2 Role of Sanofi S.A. in Global Microbiome Therapeutics Market
10.11.3 Financials
10.11.4 Key Insights About the Financial Health of the Company
10.11.5 SWOT Analysis
10.12 Seres Therapeutics, Inc.
10.12.1 Company Overview
10.12.2 Role of Seres Therapeutics, Inc. in Global Microbiome Therapeutics Market
10.12.3 Financials
10.12.4 Key Insights About Financial Health of the Company
10.12.5 SWOT Analysis
10.13 Synthetic Biologics
10.13.1 Company Overview
10.13.2 Role of Synthetic Biologics, Inc. in Global Microbiome Therapeutics Market
10.13.3 Financials
10.13.4 SWOT Analysis
10.14 Taisho Pharmaceutical
10.14.1 Company Overview
10.14.2 Biofermin Pharmaceutical Co. Ltd. (A Subsidiary of Taisho Pharmaceutical)
10.14.3 Company Overview
10.14.4 Role of Taisho Pharmaceutical in Global Microbiome Therapeutics Market
10.14.5 Financial
10.14.6 Key Insights about the Financial Health of the Company
10.14.7 SWOT Analysis
10.15 Vedanta Biosciences, Inc.
10.15.1 Company Overview
10.15.2 Role of Vedanta Biosciences, Inc. in Global Microbiome Therapeutics Market
10.15.3 SWOT Analysis
10.16 Pendulum Therapeutics
10.16.1 Company Overview
10.16.2 Role of Pendulum Therapeutics in Global Microbiome Therapeutics Market
10.16.3 SWOT Analysis
LIST OF TABLES
Table 5.1: Global Microbiome Therapeutics Market (Key Players Patent Portfolio)
Table 5.2: Patent Expiration Analysis
Table 5.3: Key Players Investors Portfolio
Table 5.4: Key Players Investors Portfolio
Table 5.5: Partnership Landscaping
Table 5.6: Government Initiatives in Microbiome Therapeutics
Table 6.1: Microbiome Collaborations
Table 9.1: EU Funding of Microbiome Research Under FP7 and H2020
Table 5.1: Global Microbiome Therapeutics Market (Key Players Patent Portfolio)
Table 5.2: Patent Expiration Analysis
Table 5.3: Key Players Investors Portfolio
Table 5.4: Key Players Investors Portfolio
Table 5.5: Partnership Landscaping
Table 5.6: Government Initiatives in Microbiome Therapeutics
Table 6.1: Microbiome Collaborations
Table 9.1: EU Funding of Microbiome Research Under FP7 and H2020
LIST OF FIGURES
Figure 1: Impact Analysis of Market Drivers and Market Challenges on Global Microbiome Therapeutics Market
Figure 2: Global Microbiome Therapeutics Market (by Target Therapy Area), $Million, 2020 and 2030
Figure 3: Global Microbiome Therapeutics Market (by Region), $Million, 2019-2030
Figure 2.1: Global Microbiome Therapeutics Market Segmentation
Figure 3.1: Global Microbiome Therapeutics Market Research Methodology
Figure 3.2: Primary Research Methodology
Figure 3.3: Bottom-Up Approach (Segment-Wise Analysis)
Figure 3.4: Top-Down Approach (Segment-Wise Analysis)
Figure 4.1: Global Microbiome Therapeutics Market, $Million, 2019-2030
Figure 4.2: Historical Evolution of Microbiome
Figure 5.1: Chemistry, Manufacturing, and Control (CMC) Information of LBPs by FDA
Figure 5.2: Patent Landscape of Microbiome Therapeutics Market (by Company and Region)
Figure 5.3: Key Players Financing Stratification
Figure 5.4: Financing Analysis, $Million, FY2017-3Q2020
Figure 5.5: Number of Pipeline Candidates (by Developmental Phase)
Figure 5.6: Number of Pipeline Candidates (by Route of Administration)
Figure 5.7: Number of Pipeline Candidates (by Type of Product)
Figure 5.8: Number of Pipeline Candidates (by Target Therapy Area)
Figure 6.1: Market Dynamics of Global Microbiome Therapeutics Market
Figure 6.2: Financing Activities Breakout, 2017-2019
Figure 6.3: Overall Financing Raised by Microbiome Companies, $Million, January 2017 – 3Q 2020
Figure 6.4: Synergistic Activities, 2017-2019
Figure 7.2: Synergistic Activities Share (by Company), January 2017-October 2020
Figure 7.3: Accreditations Share (by Company), January 2017- October 2020
Figure 7.4: Mergers and Acquisitions (by Company), January 2017- October 2020
Figure 7.5: Market Share Analysis for the Global Microbiome Therapeutics Market, 2018 and 2019
Figure 7.6: Growth Share Analysis (by Geography)
Figure 7.7: Growth Share Analysis (by Company)
Figure 8.1: Global Microbiome Therapeutics Market (by Target Therapy Area), 2020 and 2030
Figure 8.2: Number of Pipeline Candidates for Gastrointestinal and Infectious Diseases Indications
Figure 8.3: Global microbiome therapeutics market (Gastrointestinal and Infectious Diseases), 2019-2030
Figure 8.4: Global Microbiome Therapeutics Market (Other Diseases), 2023-2030
Figure 9.1: Global Microbiome Therapeutics Market (by Region), 2020 and 2030
Figure 9.2: North America Microbiome Therapeutics Market, 2019-2030
Figure 9.3: North America: Market Dynamics
Figure 9.4: North America Microbiome Therapeutics Market (by Country), 2020 and 2030
Figure 9.5: U.S. Microbiome Therapeutics Market, 2019-2030
Figure 9.6: Canada Microbiome Therapeutics Market, 2019-2030
Figure 9.7: Europe Microbiome Therapeutics Market, 2019-2030
Figure 9.8: Europe: Market Dynamics
Figure 9.9: Europe Microbiome Therapeutics Market (by Country), 2020 and 2030
Figure 9.10: France Microbiome Therapeutics Market, 2019-2030
Figure 9.11: Sweden Microbiome Therapeutics Market, 2019-2030
Figure 9.12: Germany Microbiome Therapeutics Market, 2019-2030
Figure 9.13: U.K. Microbiome Therapeutics Market, 2019-2030
Figure 9.14: Rest-of-Europe Microbiome Therapeutics Market, 2019-2030
Figure 9.15: Asia-Pacific Microbiome Therapeutics Market, 2019-2030
Figure 9.16: Asia-Pacific: Market Dynamics
Figure 9.17: Asia-Pacific Microbiome Therapeutics Market (by Country), 2020 and 2030
Figure 9.18: Japan Microbiome Therapeutics Market, 2019-2030
Figure 9.19: Australia Microbiome Therapeutics Market, 2019-2030
Figure 9.20: China Microbiome Therapeutics Market, 2019-2030
Figure 9.21: India Microbiome Therapeutics Market, 2019-2030
Figure 9.22: Rest-of-Asia-Pacific Microbiome Therapeutics Market, 2019-2030
Figure 9.23: Rest-of-the-World Microbiome Therapeutics Market, 2019-2030
Figure 10.1: Total Number of Companies Profiled
Figure 10.2: 4D Pharma plc: Overall Product Portfolio
Figure 10.3: 4D Pharma plc.: Overall Financials, 2018-2019
Figure 10.4: 4D Pharma plc: SWOT Analysis
Figure 10.5: AOBiome.: Overall Product Portfolio
Figure 10.6: AOBiome: SWOT Analysis
Figure 10.7: Finch Therapeutics: Overall Product Portfolio
Figure 10.8: Finch Therapeutics: SWOT Analysis
Figure 10.9: Rebiotix Inc.: Overall Product Portfolio
Figure 10.10: Rebiotix Inc.: SWOT Analysis
Figure 10.11: Immuron: Overall Product Portfolio
Figure 10.12: Immuron: Overall Financials, 2018-2020
Figure 10.13: Immuron: Research and Development Expenditure, 2018-2020
Figure 10.14: Immuron: SWOT Analysis
Figure 10.15: MaaT Pharma.: Overall Product Portfolio
Figure 10.16: MaaT Pharma: SWOT Analysis
Figure 10.17: Naked Biome: Overall Product Portfolio
Figure 10.18: Naked Biome: SWOT Analysis
Figure 10.19: OxThera AB: Overall Product Portfolio
Figure 10.20: OxThera AB: SWOT Analysis
Figure 10.21: Quorum Innovations, LLC: Overall Product Portfolio
Figure 10.22: Quorum Innovations, LLC: SWOT Analysis
Figure 10.23: Sanofi S.A.: Overall Product Portfolio
Figure 10.24: Sanofi S.A.: Overall Financials, 2017-2019
Figure 10.25: Sanofi S.A.: Revenue (by Segment), 2017-2019
Figure 10.26: Sanofi S.A.: Region Revenue, 2017-2019
Figure 10.27: Sanofi S.A.: Research and Development Expenditure, 2017-2019
Figure 10.28: Sanofi S.A.: SWOT Analysis
Figure 10.29: Seres Therapeutics, Inc.: Overall Product Portfolio
Figure 10.30: Seres Therapeutics, Inc.: Overall Financials, 2017-2019
Figure 10.31: Seres Therapeutics Inc.: R&D Expenditure, 2017-2019
Figure 10.32: Seres Therapeutics Inc.: SWOT Analysis
Figure 10.33: Synthetic Biologics, Inc.: Overall Product Portfolio
Figure 10.34: Synthetic Biologics, Inc.: Overall Financials, 2017-2019
Figure 10.35: Synthetic Biologics, Inc.: SWOT Analysis
Figure 10.36: Taisho Pharmaceutical Co., Ltd.: Overall Product Portfolio
Figure 10.37: Taisho Pharmaceutical Co., Ltd.: Overall Financials, 2017-2019
Figure 10.38: Taisho Pharmaceutical Co., Ltd. (by Segment), 2017-2019
Figure 10.39: Taisho Pharmaceutical Co., Ltd. (by Region), 2019
Figure 10.40: Taisho Pharmaceutical Co., Ltd.: R&D Expenditure, 2018-2019
Figure 10.41: Taisho Pharmaceutical Co., Ltd.: SWOT Analysis
Figure 10.42: Vedanta Biosciences, Inc.: Overall Product Portfolio
Figure 10.43: Vedanta Biosciences, Inc.: SWOT Analysis
Figure 10.44: Whole Genome Inc.: Overall Product Portfolio
Figure 10.45: Whole Biome Inc.: SWOT Analysis
Figure 1: Impact Analysis of Market Drivers and Market Challenges on Global Microbiome Therapeutics Market
Figure 2: Global Microbiome Therapeutics Market (by Target Therapy Area), $Million, 2020 and 2030
Figure 3: Global Microbiome Therapeutics Market (by Region), $Million, 2019-2030
Figure 2.1: Global Microbiome Therapeutics Market Segmentation
Figure 3.1: Global Microbiome Therapeutics Market Research Methodology
Figure 3.2: Primary Research Methodology
Figure 3.3: Bottom-Up Approach (Segment-Wise Analysis)
Figure 3.4: Top-Down Approach (Segment-Wise Analysis)
Figure 4.1: Global Microbiome Therapeutics Market, $Million, 2019-2030
Figure 4.2: Historical Evolution of Microbiome
Figure 5.1: Chemistry, Manufacturing, and Control (CMC) Information of LBPs by FDA
Figure 5.2: Patent Landscape of Microbiome Therapeutics Market (by Company and Region)
Figure 5.3: Key Players Financing Stratification
Figure 5.4: Financing Analysis, $Million, FY2017-3Q2020
Figure 5.5: Number of Pipeline Candidates (by Developmental Phase)
Figure 5.6: Number of Pipeline Candidates (by Route of Administration)
Figure 5.7: Number of Pipeline Candidates (by Type of Product)
Figure 5.8: Number of Pipeline Candidates (by Target Therapy Area)
Figure 6.1: Market Dynamics of Global Microbiome Therapeutics Market
Figure 6.2: Financing Activities Breakout, 2017-2019
Figure 6.3: Overall Financing Raised by Microbiome Companies, $Million, January 2017 – 3Q 2020
Figure 6.4: Synergistic Activities, 2017-2019
Figure 7.2: Synergistic Activities Share (by Company), January 2017-October 2020
Figure 7.3: Accreditations Share (by Company), January 2017- October 2020
Figure 7.4: Mergers and Acquisitions (by Company), January 2017- October 2020
Figure 7.5: Market Share Analysis for the Global Microbiome Therapeutics Market, 2018 and 2019
Figure 7.6: Growth Share Analysis (by Geography)
Figure 7.7: Growth Share Analysis (by Company)
Figure 8.1: Global Microbiome Therapeutics Market (by Target Therapy Area), 2020 and 2030
Figure 8.2: Number of Pipeline Candidates for Gastrointestinal and Infectious Diseases Indications
Figure 8.3: Global microbiome therapeutics market (Gastrointestinal and Infectious Diseases), 2019-2030
Figure 8.4: Global Microbiome Therapeutics Market (Other Diseases), 2023-2030
Figure 9.1: Global Microbiome Therapeutics Market (by Region), 2020 and 2030
Figure 9.2: North America Microbiome Therapeutics Market, 2019-2030
Figure 9.3: North America: Market Dynamics
Figure 9.4: North America Microbiome Therapeutics Market (by Country), 2020 and 2030
Figure 9.5: U.S. Microbiome Therapeutics Market, 2019-2030
Figure 9.6: Canada Microbiome Therapeutics Market, 2019-2030
Figure 9.7: Europe Microbiome Therapeutics Market, 2019-2030
Figure 9.8: Europe: Market Dynamics
Figure 9.9: Europe Microbiome Therapeutics Market (by Country), 2020 and 2030
Figure 9.10: France Microbiome Therapeutics Market, 2019-2030
Figure 9.11: Sweden Microbiome Therapeutics Market, 2019-2030
Figure 9.12: Germany Microbiome Therapeutics Market, 2019-2030
Figure 9.13: U.K. Microbiome Therapeutics Market, 2019-2030
Figure 9.14: Rest-of-Europe Microbiome Therapeutics Market, 2019-2030
Figure 9.15: Asia-Pacific Microbiome Therapeutics Market, 2019-2030
Figure 9.16: Asia-Pacific: Market Dynamics
Figure 9.17: Asia-Pacific Microbiome Therapeutics Market (by Country), 2020 and 2030
Figure 9.18: Japan Microbiome Therapeutics Market, 2019-2030
Figure 9.19: Australia Microbiome Therapeutics Market, 2019-2030
Figure 9.20: China Microbiome Therapeutics Market, 2019-2030
Figure 9.21: India Microbiome Therapeutics Market, 2019-2030
Figure 9.22: Rest-of-Asia-Pacific Microbiome Therapeutics Market, 2019-2030
Figure 9.23: Rest-of-the-World Microbiome Therapeutics Market, 2019-2030
Figure 10.1: Total Number of Companies Profiled
Figure 10.2: 4D Pharma plc: Overall Product Portfolio
Figure 10.3: 4D Pharma plc.: Overall Financials, 2018-2019
Figure 10.4: 4D Pharma plc: SWOT Analysis
Figure 10.5: AOBiome.: Overall Product Portfolio
Figure 10.6: AOBiome: SWOT Analysis
Figure 10.7: Finch Therapeutics: Overall Product Portfolio
Figure 10.8: Finch Therapeutics: SWOT Analysis
Figure 10.9: Rebiotix Inc.: Overall Product Portfolio
Figure 10.10: Rebiotix Inc.: SWOT Analysis
Figure 10.11: Immuron: Overall Product Portfolio
Figure 10.12: Immuron: Overall Financials, 2018-2020
Figure 10.13: Immuron: Research and Development Expenditure, 2018-2020
Figure 10.14: Immuron: SWOT Analysis
Figure 10.15: MaaT Pharma.: Overall Product Portfolio
Figure 10.16: MaaT Pharma: SWOT Analysis
Figure 10.17: Naked Biome: Overall Product Portfolio
Figure 10.18: Naked Biome: SWOT Analysis
Figure 10.19: OxThera AB: Overall Product Portfolio
Figure 10.20: OxThera AB: SWOT Analysis
Figure 10.21: Quorum Innovations, LLC: Overall Product Portfolio
Figure 10.22: Quorum Innovations, LLC: SWOT Analysis
Figure 10.23: Sanofi S.A.: Overall Product Portfolio
Figure 10.24: Sanofi S.A.: Overall Financials, 2017-2019
Figure 10.25: Sanofi S.A.: Revenue (by Segment), 2017-2019
Figure 10.26: Sanofi S.A.: Region Revenue, 2017-2019
Figure 10.27: Sanofi S.A.: Research and Development Expenditure, 2017-2019
Figure 10.28: Sanofi S.A.: SWOT Analysis
Figure 10.29: Seres Therapeutics, Inc.: Overall Product Portfolio
Figure 10.30: Seres Therapeutics, Inc.: Overall Financials, 2017-2019
Figure 10.31: Seres Therapeutics Inc.: R&D Expenditure, 2017-2019
Figure 10.32: Seres Therapeutics Inc.: SWOT Analysis
Figure 10.33: Synthetic Biologics, Inc.: Overall Product Portfolio
Figure 10.34: Synthetic Biologics, Inc.: Overall Financials, 2017-2019
Figure 10.35: Synthetic Biologics, Inc.: SWOT Analysis
Figure 10.36: Taisho Pharmaceutical Co., Ltd.: Overall Product Portfolio
Figure 10.37: Taisho Pharmaceutical Co., Ltd.: Overall Financials, 2017-2019
Figure 10.38: Taisho Pharmaceutical Co., Ltd. (by Segment), 2017-2019
Figure 10.39: Taisho Pharmaceutical Co., Ltd. (by Region), 2019
Figure 10.40: Taisho Pharmaceutical Co., Ltd.: R&D Expenditure, 2018-2019
Figure 10.41: Taisho Pharmaceutical Co., Ltd.: SWOT Analysis
Figure 10.42: Vedanta Biosciences, Inc.: Overall Product Portfolio
Figure 10.43: Vedanta Biosciences, Inc.: SWOT Analysis
Figure 10.44: Whole Genome Inc.: Overall Product Portfolio
Figure 10.45: Whole Biome Inc.: SWOT Analysis
